Active Ingredient(s):Empagliflozin + Linagliptin FDA Approved: * January 30, 2015 Pharm Company: *BOEHRINGER INGELHEIM Category:Diabetes
Empagliflozin/linagliptin, sold under the brand name Glyxambi, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes. It is a combination of empagliflozin and linagliptin. It is taken by mouth.
The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections .
It was ...
* May have multiple approval dates, manufacturers, or labelers.